NCT00973323View on ClinicalTrials.gov

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

March 31, 2006

Conditions

Atrial Fibrillation

Interventions

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

2.5mg bid

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

5mg bid

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

10mg bid

DRUG

Warfarin

Dose-adjusted warfarin based on target INR values

Trial Locations (10)

910-0005

Fukui-shi

830-8577

Kurume

819-1104

Maebaru-chūō

061-1134

Kitahiroshima

085-0831

Kushiro

064-0807

Sapporo

923-1100

Nomi

227-0046

Yokohama

870-0192

Ōita

359-1141

Tokorozawa

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY